SCHEMBL5607840

SCHEMBL5607840

N[C@@H](Cc1ccc(CNS(=O)(=O)c2ccccc2)cc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.61
CA12 O43570 2/20 0.60
CA9 Q16790 2/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
SLC7A5 Q01650 2/20 0.58
ALPI P09923 1/20 0.58
PKM P14618 1/20 0.58
PTGS1 P23219 1/20 0.58
XIAP P98170 1/20 0.58
PRMT1 Q99873 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
LMNA P02545 2/20 0.54
CXCR4 P61073 1/20 0.52
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 2/20 0.48
HTT P42858 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27754918 1.00 KEAP1 (0.61) KEAP1CA12CA9CA1CA2
SCHEMBL5079182 0.92 MMP2 (0.56) KEAP1CA12CA9CA1CA2
SCHEMBL27734539 0.89 CA9 (0.50) KEAP1CA12CA9CA1CA2
SCHEMBL27734537 0.89 CA9 (0.50) KEAP1CA12CA9CA1CA2
SCHEMBL5608193 0.88 LMNA (0.62) CA12CA9SMN1; SMN2LMNACYP1A2
SCHEMBL27755098 0.88 ALDH1A1 (0.54) CA12CA9CA1CA2SLC7A5
SCHEMBL5607879 0.88 ALDH1A1 (0.54) CA12CA9CA1CA2SLC7A5
SCHEMBL27734721 0.86 HSD11B1 (0.60) SMN1; SMN2LMNAL3MBTL1ITGB1ITGA4
SCHEMBL5078485 0.86 HSD11B1 (0.60) SMN1; SMN2LMNAL3MBTL1ITGB1ITGA4
SCHEMBL8232101 0.84 TSHR (0.67) CA2SMN1; SMN2LMNAHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP KEAP1 2321/4885CA12 3903/4885CA9 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.